:Long acting injectable (LAI) antipsychotics are indicated for individuals suffering from schizophrenia, delusional disorder, schizoaffective disorder and bipolar disorder. Even though LAIs have traditionally been used for a subgroup of patients who were not compliant with oral treatments or who were a high risk to others, current trends are changing with increased options and availability of these treatments. A number of factors are implicated in the reversal of this trend including perspectives of patients and perspectives of providers. There is not abundant literature available regarding robust studies to examine these perspectives, but this presentation provides a current summary of available literature.Some factors that influence perspectives of both patients and providers include knowledge about LAIs, cost of LAIs and the traditional views of these agents as being used under coercive circumstances. Altering perspectives has been a primary barrier to increase the use of these agents. Evidence clearly supports the use of early intervention for individuals with first episode psychosis, and poor medication compliance results in poorer treatment outcomes. With the potential improvement in quality of life and potentially decreasing the cost burden of this illness in society, this avenue for treatment must be a strong consideration for all involved in the treatment of the aforementioned disorders.

中文翻译：

---

141 长效注射剂使用抗精神病药的缓和观点：文献回顾

：长效可注射 (LAI) 抗精神病药物适用于患有精神分裂症、妄想症、分裂情感障碍和双相情感障碍的个体。尽管 LAI 传统上被用于不依从口服治疗或对其他人具有高风险的患者亚组，但随着这些治疗的选择和可用性的增加，当前趋势正在发生变化。许多因素与这一趋势的逆转有关，包括患者的观点和提供者的观点。没有丰富的文献可用于检验这些观点的稳健研究，但本演示文稿提供了现有文献的当前摘要。影响患者和提供者观点的一些因素包括关于 LAI 的知识、LAI 的成本以及这些代理人在强制情况下使用的传统观点。改变观点一直是增加这些药物使用的主要障碍。证据明确支持对首发精神病患者进行早期干预，药物依从性差会导致治疗效果较差。随着生活质量的潜在改善和这种疾病在社会上的成本负担的潜在降低，这种治疗途径必须成为所有参与上述疾病治疗的人的强烈考虑。药物依从性差会导致较差的治疗结果。随着生活质量的潜在改善和这种疾病在社会上的成本负担的潜在降低，这种治疗途径必须成为所有参与上述疾病治疗的人的强烈考虑。药物依从性差会导致较差的治疗结果。随着生活质量的潜在改善和这种疾病在社会上的成本负担的潜在降低，这种治疗途径必须成为所有参与上述疾病治疗的人的强烈考虑。